Fenofibrate/pitavastatin - Hanlim Pharmaceutical

Drug Profile

Fenofibrate/pitavastatin - Hanlim Pharmaceutical

Alternative Names: Livasupril; Pitavastatin/fenofibrate

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hanlim Pharmaceutical
  • Class Antihyperlipidaemics; Benzophenones; Butyric acids; Carboxylic acids; Cyclopropanes; Fibric acid derivatives; Fluorobenzenes; Propionates; Quinolines; Small molecules
  • Mechanism of Action HMG-CoA reductase inhibitors; Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Unspecified

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Undefined(In volunteers) in South Korea (PO, Capsule)
  • 01 Sep 2014 Phase-I clinical trials in Undefined indication (In volunteers) in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top